Kymera Perspectives

Hear from our team on recent breakthroughs, scientific and clinical advancements, company culture, and our ongoing work to develop new medicines at Kymera.

Noah Goodman April2026 Blog Feature
April 15, 2026

For biotech companies, advancing innovation doesn’t happen in isolation. It depends on an interconnected ecosystem to move transformative science forward. That’s true for Kymera too.

Following our recent milestone announcement regarding our collaboration with Gilead on our novel oral CDK2 molecular glue degrader, learn more from our Chief Business Officer, Noah Goodman, about the rapidly evolving partnership landscape, what makes collaborations work, and where he sees the industry heading over the next decade.

Read More

Featured

April 15, 2026
A Conversation with Kymera’s Chief Business Officer, Noah Goodman
Noah Goodman, MBA, Chief Business Officer
See More
April 24, 2025
A New Era of Possibility: Addressing Coveted Undrugged Targets
Juliet Williams, PhD, Head of Research
See More
June 11, 2025
Powering Possibility Through Oral Medicines with Biologics-like Profiles
Nello Mainolfi, PhD, Founder, President and CEO
See More
Icon_In-the-News
Discover Our Latest Milestones

Stay ahead with the latest news from Kymera. Our Press Releases provide insights into our recent achievements and future endeavors.

  • Area of Focus

Related Stories